Assembly Biosciences, Inc. (ASMB)

USD 14.18

(23.95%)

Market Cap (In USD)

106.39 Million

Revenue (In USD)

7.16 Million

Net Income (In USD)

-61.22 Million

Avg. Volume

27.18 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
9.12-19.93
PE
-2.12
EPS
-6.69
Beta Value
0.588
ISIN
US0453962070
CUSIP
045396108
CIK
1426800
Shares
7503390.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jason A. Okazaki
Employee Count
-
Website
https://www.assemblybio.com
Ipo Date
2010-12-17
Details
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.